Microbix Biosystms (TSE:MBX) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Microbix Biosystems Inc. has achieved record revenues of $25.4 million for fiscal year 2024, driven by a 42% increase in sales of its Antigens and QAPs products. The company reports a net income of $3.5 million, highlighting its successful growth and optimistic future outlook in the diagnostic-test market.
For further insights into TSE:MBX stock, check out TipRanks’ Stock Analysis page.
